戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 y and dynamic complexity were unique to each tested drug.
2 ression throughout the years or evaluate any tested drugs.
3 s between these two methods was 100% for all tested drugs.
4         All isolates were susceptible to all tested drugs.
5 This study also highlights the importance of testing drug activity in biological matrices as well as
6 predicted long-term recovery better than any tested drug after thoracic SCI in rats.
7 istology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic g
8                          Investigating how a test drug alters the reaction of a site-directed electro
9 ormed before and after the first dose of the test drug and again after 4 weeks of therapy.
10 Generalized Estimation Equation model, using test drug and evaluation times, along with an interactio
11 tudy methods to manipulate hemorrhage and to test drugs and devices for safety, because the rabbit mo
12 e, parasite tropism, and pathogenesis and to test drugs and vaccines against naturally acquired VL.
13 86N mutation increased resistance to all the tested drugs and augmented the effect of G185V on etopos
14  Administration (FDA)-approved or clinically tested drugs and identified drugs that synergize to inhi
15                             In a total of 22 tested drugs and metabolites, 21 analytes were detected
16 to treat malaria through repurposing of time-tested drugs and rigorous design of new drugs using tool
17 opens new opportunities to develop vaccines, test drugs, and clone parasites for genome sequencing.
18 velopment, studying cardiovascular diseases, testing drugs, and transplantation.
19  hamster models because (i) lower amounts of test drugs are needed, (ii) more animals can be housed i
20  might render infeasible existing models for testing drugs before disease onset.
21 rdization, starting with the most frequently tested drugs, BL antibiotics.
22                        Phase II studies have tested drugs blocking EGFR, vascular endothelial growth
23 es such as the NCI-60 have long been used to test drug candidates for their ability to inhibit prolif
24 cancer, and they are now extensively used to test drug candidates, predict drug responses, and essent
25 directed evolution of arginase libraries and testing drug candidates for arginase inhibition.
26                                        Among tested drugs, cefoxitin and tigecycline showed promising
27 cillin allergy label: (1) perform diagnostic testing (drug challenges, with or without skin tests); a
28 agent alone, contrasting markedly with other tested drug combinations.
29 tablish the use of Rgs16::GFP expression for testing drug combinations in cell culture and validation
30                                  None of the tested drugs completely displaced DAUDA from hFABP1, and
31 gy has performed a literature search on skin test drug concentration in MEDLINE and EMBASE, reviewed
32  at approximately 50% of neurite tips at all tested drug concentrations (1-10 muM).
33                   MorphEUS classified 94% of tested drugs correctly into broad categories according t
34 itro models offer much promise for research, testing drugs, cosmetics, and medical devices, reducing
35 idic tools allow new ways to manufacture and test drug delivery systems.
36 ity of spheroids as an in vitro platform for testing drug delivery systems.
37 ue for characterization, access to molecular testing, drug delivery across the blood-brain barrier (B
38 ited 90% of the isolates for the majority of tested drug-dermatophyte combinations.
39 ar and angiogenic neoplasias, as well as for testing drugs designed to curtail aberrant EC growth.
40 cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling.
41 ensitive, robust, and efficient platform for testing drug effectiveness and for arrhythmia screening.
42                           This allowed us to test drug effects, expectancy (knowledge) effects, and t
43 involved in bone colonization and to rapidly test drug efficacies on bone micrometastases.
44 erface (FMi) barrier, and reliable models to test drug efficacy and other pharmacologic parameters ha
45 y sex, clinical trials should be designed to test drug efficacy and safety according to sex, age, rep
46 iques for monitoring disease progression and testing drug efficacy in animal models of inflammatory a
47 re we describe a rapid label-free method for testing drug efficacy in vitro that evaluates cellular v
48  the in vivo tumor microenvironment; and (4) test drug efficiency in an in vitro model that is compar
49                                          All test drugs evoke fluoxetine-sensitive efflux of [(3)H]5-
50 nd fentanyl test strips (FTS) can be used to test drugs for fentanyl at the point of consumption.
51 is mouse model provides an important tool to test drugs for their potential to cause hemolytic toxici
52                               Rats were then tested drug free during an extinction test.
53 ats were conditioned with 1.0 mg/kg AMPH and tested, drug free, 72 h after the last conditioning sess
54                      However, when rats were tested drug-free 24 h after OFC inactivation and reversa
55 g in sustained freezing when mice were later tested drug-free.
56     This approach identified the effect of a test drug (GABA-reuptake inhibitor, tiagabine) on neuron
57                                 However, the tested drugs have limited specificity and efficacy so th
58 d into two groups (n = 20), according to the test drug (ibuprofen and nimesulide) to be administered
59           The main problem was to retain the test drug in situ without extraneous irritation from the
60                     Accordingly, in order to test drugs in a human context, we have developed a platf
61         While it is undoubtedly important to test drugs in these animal models, additional evidence f
62                                          All tested drugs inhibited KcsA activity, and the changes in
63 (OR: 0.33; 95% CI: 0.09 to 0.91; p = 0.039), tested drug interventions (OR: 0.42; 95% CI: 0.16 to 0.9
64 were coordinated in North America or Europe, tested drug interventions, or had men as senior authors.
65                           The effects of the test drugs on COX-2 and PPAR gamma expression and on the
66 al, jugular catheters were injected with the test drug or 0.9% NaCl (saline), and blood samples were
67 different times, and were randomly given the test drug or placebo in a split-mouth design.
68 ia parasites to study immune response and/or test drug or vaccine efficacy, are increasingly being co
69 hospecific antibodies responded similarly to test drugs or light.
70 ing mechanistic studies and, if refined, for testing drugs or small molecules for personalized medici
71 udying the mechanism of this disease and for testing drugs or therapies for treating osteoarthritis.
72                                 In all three tested drug pairs, the alternating treatment reduced the
73 showed limited penetration of the clinically tested drug perifosine into spheroids during a 24 h peri
74 echanisms, identify therapeutic targets, and test drugs pre-clinically.
75  This study confirms that although all three test drugs produced significant antinociception at 10 mi
76 l cultures by 80 FDA-approved and clinically tested drugs, producing a ranked list of possible repurp
77                                     Exercise testing, drug provocation, advanced cardiac imaging, and
78 ting (HIVST) versus standard of care for HIV testing, drug refilling, and adherence among PrEP users.
79                    We developed a method for testing drug rotation protocols in CML cell lines based
80 he population of bacteria susceptible to the test drug, S the population susceptible only to steriliz
81 ther conducted a focused secondary screen to test drug sensitivity for ~1,400 gene targets across two
82  We used patient-derived organoids (PDOs) to test drug sensitivity to MET, MEK, and CDK4/6 inhibitors
83                  Adequate infrastructure for testing drug sensitivity and sufficient evidence of firs
84 mercially available recombinant virus assays test drug susceptibility of virus pools.
85                                        Sites tested drug susceptibility using routinely available met
86 atform is simple to operate and multiplex to test drugs targeting angiogenesis in a more physiologica
87 ht opens the possibility of using clinically tested drugs, targeting the Wnt/beta-catenin pathway, fo
88  The spontaneous OA dog model may be used to test drugs that normalize EPM function.
89 ng ways to improve respiration after SCI, we tested drugs that stimulate serotonin 1A (5-HT1A) recept
90 sed biomarkers in clinical trials as well as testing drugs that modulate APP processing as potential
91 hology in vitro represents a new approach to testing drugs that will help accelerate the development
92  International regulatory agencies recommend testing drug therapy for patients with noncirrhotic high
93  cell preparations, the selectivities of the tested drugs toward endothelial cell over platelet COX-1
94 eir applications to model liver diseases and test drug toxicity in vitro.
95 armaceutical company policies that routinely test drugs under development; if a candidate drug shows
96                      The risk profile of the test drugs was similar across hiPSC-CMs derived from dif
97 mpathetic nerves innervating the ventricles, test drugs were introduced into the pericardial sac for
98 Mini 11 gave LOQs of 10-20 ng mL(-1) for the tested drugs, which is sufficient to cover the therapeut
99  To establish a preclinical animal model for testing drugs with potential effects on myeloproliferati